SAVA Cassava Sciences

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Conference call and webcast to begin at 8:30 AM ET

AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.

  
Event details:
  
Date:Thursday, November 7th
Time:8:30 a.m. Eastern Time
Audio Webcast:
Or
Audio Webcast:
  

A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit:

For More Information Contact:

Investors

Sandya van der Weid

Media

Sitrick And Company



Company

Eric Schoen, Chief Financial Officer

(512) 501-2450



EN
31/10/2024

Underlying

SAVACassava Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Closure of U.S. Department of Justice Investigation

Cassava Announces Closure of U.S. Department of Justice Investigation AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-...

February 19, 2026 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Sim...

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints  The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company...

January 13, 2026 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Agreement to Settle Securities Class Action Litigati...

Cassava Announces Agreement to Settle Securities Class Action Litigation AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austi...

December 23, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Reports Q3 2025 Financials Results and Provides Business Updat...

Cassava Reports Q3 2025 Financials Results and Provides Business Update Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigation...

November 12, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value ...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch